Key result
VICTOR successfully enrolls a contemporary HFrEF population with ~59% receiving SGLT2 inhibitors.
Why the study?
To describe the baseline characteristics of participants in the VICTOR trial and compare them to recent trials in patients with heart failure and reduced ejection fraction.
RCT
Yes
Answers are grounded in this paper and cite their sources.
VICTOR participants reflect high contemporary GDMT use; extends vericiguat evaluation to less-hospitalized HFrEF.
AIMS: To describe the baseline characteristics of the participants in the VICTOR (Vericiguat Global Study in Patients with Chronic Heart Failure; NCT05093933) trial and compare them to recent trials in patients with heart failure and reduced ejection fraction (HFrEF). METHODS AND Median N-terminal pro-B-type natriuretic peptide level was 1476 (970-2495) pg/ml and 47.5% of participants had no prior hospitalization for heart failure. Baseline therapy included 94.4% beta-blockers, 94.3% renin-angiotensin system modulation (including 56.0% on an angiotensin receptor-neprilysin inhibitor), 77.7% mineralocorticoid receptor antagonists, 59.1% sodium-glucose cotransporter 2 inhibitors, and 32.9% implantable cardioverter-defibrillators. Overall characteristics were relatively similar to other recent HFrEF trials but the VICTOR trial enrolled a higher proportion of participants receiving contemporary drug and device therapy. CONCLUSION: The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.
No takes yet. Share an insight, caveat, or question.
Saldarriaga et al. (2025) conducted an RCT in Chronic heart failure with reduced ejection fraction (HFrEF). Vericiguat was evaluated. The VICTOR trial of vericiguat enrolled patients with HFrEF receiving highly optimized contemporary therapy, including 59.1% on SGLT2 inhibitors and 56.0% on ARNIs.
Synapse has enriched 10 related papers. Consider them for comparative context: